Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 322.53
ACHN's Cash to Debt is ranked higher than
76% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. ACHN: 322.53 )
ACHN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 322.53

F-Score: 2
Z-Score: 41.88
M-Score: -4.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -50.71
ACHN's ROE (%) is ranked higher than
66% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. ACHN: -50.71 )
ACHN' s 10-Year ROE (%) Range
Min: -199.15   Max: -46.56
Current: -50.71

-199.15
-46.56
ROA (%) -47.07
ACHN's ROA (%) is ranked higher than
63% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. ACHN: -47.07 )
ACHN' s 10-Year ROA (%) Range
Min: -181.02   Max: -43.23
Current: -47.07

-181.02
-43.23
ROC (Joel Greenblatt) (%) -4805.90
ACHN's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. ACHN: -4805.90 )
ACHN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6066.62   Max: -465.75
Current: -4805.9

-6066.62
-465.75
EBITDA Growth (3Y)(%) 1.00
ACHN's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ACHN: 1.00 )
ACHN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 4.1
Current: 1

0
4.1
EPS Growth (3Y)(%) 0.50
ACHN's EPS Growth (3Y)(%) is ranked higher than
79% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. ACHN: 0.50 )
ACHN' s 10-Year EPS Growth (3Y)(%) Range
Min: -65.5   Max: 3.4
Current: 0.5

-65.5
3.4
» ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ACHN Guru Trades in Q1 2014

Steven Cohen 43,533 sh (New)
Paul Tudor Jones Sold Out
Jean-Marie Eveillard Sold Out
Chuck Royce 500,000 sh (-15.25%)
» More
Q2 2014

ACHN Guru Trades in Q2 2014

Paul Tudor Jones 26,592 sh (New)
Steven Cohen 547,200 sh (unchged)
Chuck Royce 2,262 sh (-99.55%)
» More
Q3 2014

ACHN Guru Trades in Q3 2014

Jim Simons 897,300 sh (New)
Steven Cohen 1,048,100 sh (+91.54%)
Paul Tudor Jones 45,217 sh (+70.04%)
Chuck Royce 2,262 sh (unchged)
» More
Q4 2014

ACHN Guru Trades in Q4 2014

John Burbank 36,104 sh (New)
John Burbank 207,000 sh (unchged)
Chuck Royce Sold Out
Jim Simons Sold Out
Steven Cohen 621,900 sh (-40.66%)
Paul Tudor Jones 13,942 sh (-69.17%)
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.62
ACHN's P/B is ranked higher than
61% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. ACHN: 6.62 )
ACHN' s 10-Year P/B Range
Min: 0.79   Max: 17.77
Current: 6.62

0.79
17.77
EV-to-EBIT -13.26
ACHN's EV-to-EBIT is ranked higher than
61% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACHN: -13.26 )
ACHN' s 10-Year EV-to-EBIT Range
Min: -25.5   Max: 0.6
Current: -13.26

-25.5
0.6
Current Ratio 11.86
ACHN's Current Ratio is ranked higher than
89% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ACHN: 11.86 )
ACHN' s 10-Year Current Ratio Range
Min: 1.06   Max: 13.27
Current: 11.86

1.06
13.27
Quick Ratio 11.86
ACHN's Quick Ratio is ranked higher than
90% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. ACHN: 11.86 )
ACHN' s 10-Year Quick Ratio Range
Min: 1.06   Max: 13.27
Current: 11.86

1.06
13.27

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.76
ACHN's Price/Net Cash is ranked higher than
83% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 86.70 vs. ACHN: 6.76 )
ACHN' s 10-Year Price/Net Cash Range
Min: 0.82   Max: 12.7
Current: 6.76

0.82
12.7
Price/Net Current Asset Value 6.66
ACHN's Price/Net Current Asset Value is ranked higher than
82% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 39.00 vs. ACHN: 6.66 )
ACHN' s 10-Year Price/Net Current Asset Value Range
Min: 0.78   Max: 12.29
Current: 6.66

0.78
12.29
Price/Tangible Book 6.62
ACHN's Price/Tangible Book is ranked higher than
70% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. ACHN: 6.62 )
ACHN' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 77.75
Current: 6.62

0.72
77.75
Earnings Yield (Greenblatt) -7.50
ACHN's Earnings Yield (Greenblatt) is ranked higher than
63% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. ACHN: -7.50 )
ACHN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 176.4   Max: 2697.4
Current: -7.5

176.4
2697.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
comment on ACHN Mar 15 2013 
comment on ACHN Mar 09 2013 
Achillion Will Surge If New Drug Is Successful Apr 21 2012 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 

More From Other Websites
Gilead, Achillion Pharma In Race Against Time To Lower HCV Treatment Duration May 01 2015
Achillion to Present at Two Upcoming Investor Conferences Apr 30 2015
Achillion to Present at Two Upcoming Investor Conferences Apr 30 2015
Nasdaq stocks posting largest percentage decreases Apr 29 2015
Most active Nasdaq-traded stocks Apr 29 2015
Pharmalot.. Pharmalittle.. Good Morning: We're Catching up on Gilead, Merck and Lots More!! Apr 29 2015
Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver... Apr 25 2015
Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver... Apr 25 2015
Achillion Announces Upcoming Presentations at the International Liver Congress 2015 (EASL) Apr 08 2015
Achillion Announces Upcoming Presentations at the International Liver Congress 2015 (EASL) Apr 08 2015
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals... Mar 30 2015
Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the... Mar 30 2015
Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog Mar 27 2015
Steadymed Ltd (STDY), Achillion Pharmaceuticals, Inc. (ACHN), & Nevro Corp (NVRO): James Flynn’s... Mar 27 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 24 2015
Lightning Round: Too much competition in this Mar 20 2015
Cramer Remix: Cha-ching! Time to cash in Mar 20 2015
ACHILLION PHARMACEUTICALS INC Financials Mar 13 2015
Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog Mar 11 2015
10-K for Achillion Pharmaceuticals, Inc. Mar 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK